Authors: Martha Powell, Future Science Group
World AIDS day is celebrated worldwide on December 1st and to help advocate the cause, we’re turning our focus on Infectious Diseases Hub to HIV and AIDS throughout December.
In this interview we speak to Richard Koup, Senior Investigator and Chief of the Immunology lab at the Vaccine Research Center, National Institute of Allergy and Infectious Diseases (MD, USA), who was recently an author on a study reporting a trispecific antibody able to target 99% of HIV strains.
Richard has focused on HIV-related research throughout his career, initially at the Aaron Diamond AIDS Research Center (NY, USA) and then as Chief of Infectious Diseases at UT Southwestern Medical Center (TX, USA). Here, Richard talks about the conclusions and implications of this research, in addition to giving his thoughts on the future of HIV treatment and prevention. Find out more below.
00.23 – Introductions
01.07 – You were an author on the recent paper “Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques” – could you give a quick introduction to the project and outline your rationale for investigating this area?
04.45 – What were most important conclusions from the study?
05.26 – What are the next steps for this antibody? And in the future how do you hope this therapeutic might affect clinical management of HIV?
06.22 – Do you feel this is more promising approach to HIV treatment and prevention than others, such as mosaic vaccines or pre-exposure prophylaxis, or are these all valuable methods to continue investigating at present?
07.53 – Do you think this antibody approach could also be applicable to other diseases or conditions?
09.46 – What do you consider to be the greatest challenges hindering the field of HIV treatment and prevention? And how might these be overcome?
11.02 – Do you have any additional thoughts or comments you’d like to add?